Phosphosulindac Ocular Formulations for Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye disease and diabetic retinopathy, including corticosteroids and NSAIDs, have limited efficacy and are associated with significant side effects such as elevated intraocular pressure, corneal melt, and poor patient compliance, necessitating the development of safer and more effective therapeutic options.
Innovation Solution
The use of phosphosulindac (PS) and its derivatives as topical formulations, potentially combined with antibiotics like cyclosporine and lifitegrast, to treat dry eye disease and diabetic retinopathy, which are administered in eye drops or other ocular formulations to provide analgesic and anti-inflammatory effects without causing corneal melt.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids are used to treat dry eye disease and ocular inflammation, then anti-inflammatory efficacy is improved, but intraocular pressure elevation and cataract formation risk increase
Solution Approach 1:
The patent modifies the chemical structure of traditional NSAIDs by introducing a phospho-ester group, creating phosphosulindac and its derivatives. This parameter change in molecular structure allows the compound to achieve anti-inflammatory effects while reducing the harmful side effects of intraocular pressure elevation and corneal melt associated with conventional NSAIDs
Solution Approach 2:
The invention combines the phospho-ester prodrug moiety with the sulindac core structure, creating a composite molecular entity that exhibits both the desired anti-inflammatory activity and reduced toxicity profile. The phospho-ester group acts as a protective mask that is converted in vivo to release the active sulindac metabolite
2Reliability
If NSAIDs are used to treat ocular inflammation and pain, then analgesic and anti-inflammatory effects are improved, but corneal melt risk increases
Solution Approach 1:
The patent modifies the chemical structure of traditional NSAIDs by introducing a phospho-ester group, creating phosphosulindac and its derivatives. This parameter change in molecular structure allows the compound to achieve anti-inflammatory effects while reducing the harmful side effects of intraocular pressure elevation and corneal melt associated with conventional NSAIDs
Solution Approach 2:
The phospho-ester group serves as an intermediary prodrug moiety that modifies the pharmacological profile of sulindac. This intermediary structure reduces the direct contact and harmful effects on the cornea while maintaining the therapeutic anti-inflammatory and analgesic actions through in vivo conversion to active metabolites
3Duration of action of moving object
If topical corticosteroids are used for extended periods to treat dry eye conditions, then anti-inflammatory relief is improved, but cataract formation and IOP elevation risk increase
Solution Approach 1:
The patent modifies the chemical structure of traditional NSAIDs by introducing a phospho-ester group, creating phosphosulindac and its derivatives. This parameter change in molecular structure allows the compound to achieve anti-inflammatory effects while reducing the harmful side effects of intraocular pressure elevation and corneal melt associated with conventional NSAIDs
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to compositions and methods for treating ophthalmic conditions.